“The lack of understanding around the scope and intent of Directive 2001/83/EC of the European Parliament is responsible for the existing debate and controversy concerning section 3(d) of the Indian ...
India's Section 107A (Bolar exemption) allows generics to conduct R&D on patented drugs for regulatory approval, accelerating market entry after patent expiry. “The principle behind the Bolar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback